Market Study on Biosimilar Insulin: More Than 80% Market Share Accounted for by Insulin Glargine

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,900	250 Pages	Future Market Insights	July, 2022	FMARI17378840

Best Price Guarantee
Price	from $4,900
Length	250 Pages
Publisher	Future Market Insights
Published Date	July, 2022
SKU	FMARI17378840

Market Study on Biosimilar Insulin: More Than 80% Market Share Accounted for by Insulin Glargine

Biosimilar insulin Market: Scope of Report

The latest publication by Persistence Market Research on the global biosimilar insulin market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for biosimilar insulin market products and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the biosimilar insulin market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the biosimilar insulin market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the biosimilar insulin market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research’s study on the biosimilar insulin market offers information divided into three important segments – product, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Product

Insulin Glargine
Insulin Analog
Others
Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Region

North America
Latin America
Europe
APAC
MEA
Key Questions Answered in Report

Which regions will continue to remain the most profitable markets for biosimilar insulin over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the biosimilar insulin market avail themselves the growth opportunities in developed and emerging sectors?
Research Methodology

In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the biosimilar insulin market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the biosimilar insulin market more accurate and reliable.

1. Executive Summary: 1.1. Global Market Outlook; 1.2. Demand Side Trends; 1.3. Supply Side Trends; 1.4. Analysis and Recommendations
2. Market Overview: 2.1. Market Coverage / Taxonomy; 2.2. Market Definition / Scope / Limitations; 2.3. Inclusion And Exclusions
3. Key Market Trends: 3.1. Key Trends Impacting the Market; 3.2. Product Innovation / Development Trends
4. Key Success Factors: 4.1. Key Products USP/Feature Analysis; 4.2. Regulatory Scenario; 4.3. Key Promotional Strategies By Manufacturers; 4.4. Recent Product Launches; 4.5. Value Chain Analysis; 4.6. Product Adoption Analysis by Region
5. Market Background: 5.1. Macro-Economic Factors; 5.1.1. Global GDP Growth Outlook; 5.1.2. Global Healthcare Industry Outlook; 5.1.3. Parent Market Analysis (Insulin Market); 5.2. Forecast Factors - Relevance & Impact; 5.2.1. Growing Prevalence Of Diabetes; 5.2.2. Increasing Research and Development Activities; 5.2.3. New Product Launches; 5.2.4. Increasing Number Of Clinical Trials; 5.2.5. Patent Expiry for Insulin; 5.2.6. Growing Geriatric Population; 5.2.7. Increasing Insulin Manufacturers; 5.2.8. Requirement of Cost-Efficient Products; 5.3. Market Dynamics; 5.3.1. Drivers; 5.3.2. Restraints; 5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis: 6.1. 2021 Market Scenario; 6.2. COVID-19 and Impact Analysis; 6.2.1. By Product; 6.2.2. By Distribution Channel; 6.2.3. By Region
7. Global Biosimilar Insulin Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032: 7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021; 7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032; 7.2.1. Y-o-Y Growth Trend Analysis; 7.2.2. Absolute $ Opportunity Analysis
8. Global Biosimilar Insulin Market - Pricing Analysis: 8.1. Regional Pricing Analysis By Product; 8.2. Global Average Pricing Analysis Benchmark; 8.3. Pricing Break-up; 8.3.1. Manufacturer Level Pricing; 8.3.2. Distributor Level Pricing; 8.4. Pricing Assumptions
9. Global Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032, By Product: 9.1. Introduction / Key Findings; 9.2. Historical Market Size (US$ Mn) Analysis By Product, 2017–2021; 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2032; 9.3.1. Insulin Glargine; 9.3.2. Insulin Analog; 9.3.3. Others; 9.4. Market Attractiveness Analysis By Product
10. Global Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel: 10.1. Introduction / Key Findings; 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2017–2021; 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022–2032; 10.3.1. Hospital Pharmacies; 10.3.2. Retail Pharmacies; 10.3.3. Online Pharmacies; 10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032, By Region: 11.1. Introduction; 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2021; 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032; 11.3.1. North America; 11.3.2. Latin America; 11.3.3. Europe; 11.3.4. Asia Pacific (APAC); 11.3.5. Middle East and Africa (MEA); 11.4. Market Attractiveness Analysis By Region
12. North America Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032: 12.1. Introduction; 12.2. Pricing Analysis; 12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021; 12.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032; 12.4.1. By Country; 12.4.1.1. U.S.; 12.4.1.2. Canada; 12.4.2. By Product; 12.4.3. By Distribution Channel; 12.5. Market Attractiveness Analysis; 12.5.1. By Country; 12.5.2. By Product; 12.5.3. By Distribution Channel; 12.6. Key Market Participants - Intensity Mapping; 12.7. Drivers and Restraints - Impact Analysis; 12.8. Country Level Analysis & Forecast; 12.8.1. U.S. Biosimilar Insulin Market; 12.8.1.1. Introduction; 12.8.1.2. Market Analysis and Forecast by Market Taxonomy; 12.8.1.2.1. By Product; 12.8.1.2.2. By Distribution Channel; 12.8.2. Canada Biosimilar Insulin Market; 12.8.2.1. Introduction; 12.8.2.2. Market Analysis and Forecast by Market Taxonomy; 12.8.2.2.1. By Product; 12.8.2.2.2. By Distribution Channel
13. Latin America Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032: 13.1. Introduction; 13.2. Pricing Analysis; 13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021; 13.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032; 13.4.1. By Country; 13.4.1.1. Brazil; 13.4.1.2. Argentina; 13.4.1.3. Mexico; 13.4.1.4. Rest of Latin America; 13.4.2. By Product; 13.4.3. By Distribution Channel; 13.5. Market Attractiveness Analysis; 13.5.1. By Country; 13.5.2. By Product; 13.5.3. By Distribution Channel; 13.6. Key Market Participants - Intensity Mapping; 13.7. Drivers and Restraints - Impact Analysis; 13.8. Country Level Analysis & Forecast; 13.8.1. Brazil Biosimilar Insulin Market; 13.8.1.1. Introduction; 13.8.1.2. Market Analysis and Forecast by Market Taxonomy; 13.8.1.2.1. By Product; 13.8.1.2.2. By Distribution Channel; 13.8.2. Argentina Biosimilar Insulin Market; 13.8.2.1. Introduction; 13.8.2.2. Market Analysis and Forecast by Market Taxonomy; 13.8.2.2.1. By Product; 13.8.2.2.2. By Distribution Channel; 13.8.3. Mexico Biosimilar Insulin Market; 13.8.3.1. Introduction; 13.8.3.2. Market Analysis and Forecast by Market Taxonomy; 13.8.3.2.1. By Product; 13.8.3.2.2. By Distribution Channel
14. Europe Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032: 14.1. Introduction; 14.2. Pricing Analysis; 14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021; 14.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032; 14.4.1. By Country; 14.4.1.1. Germany; 14.4.1.2. Italy; 14.4.1.3. France; 14.4.1.4. U.K.; 14.4.1.5. Spain; 14.4.1.6. BENELUX; 14.4.1.7. Nordic Countries; 14.4.1.8. Russia; 14.4.1.9. Rest of Europe; 14.4.2. By Product; 14.4.3. By Distribution Channel; 14.5. Market Attractiveness Analysis; 14.5.1. By Country; 14.5.2. By Product; 14.5.3. By Distribution Channel; 14.6. Key Market Participants - Intensity Mapping; 14.7. Drivers and Restraints - Impact Analysis; 14.8. Country Level Analysis & Forecast; 14.8.1. Germany Biosimilar Insulin Market; 14.8.1.1. Introduction; 14.8.1.2. Market Analysis and Forecast by Market Taxonomy; 14.8.1.2.1. By Product; 14.8.1.2.2. By Distribution Channel; 14.8.2. France Biosimilar Insulin Market; 14.8.2.1. Introduction; 14.8.2.2. Market Analysis and Forecast by Market Taxonomy; 14.8.2.2.1. By Product; 14.8.2.2.2. By Distribution Channel; 14.8.3. Italy Biosimilar Insulin Market; 14.8.3.1. Introduction; 14.8.3.2. Market Analysis and Forecast by Market Taxonomy; 14.8.3.2.1. By Product; 14.8.3.2.2. By Distribution Channel; 14.8.4. Spain Biosimilar Insulin Market; 14.8.4.1. Introduction; 14.8.4.2. Market Analysis and Forecast by Market Taxonomy; 14.8.4.2.1. By Product; 14.8.4.2.2. By Distribution Channel; 14.8.5. U.K. Biosimilar Insulin Market; 14.8.5.1. Introduction; 14.8.5.2. Market Analysis and Forecast by Market Taxonomy; 14.8.5.2.1. By Product; 14.8.5.2.2. By Distribution Channel; 14.8.6. BENULUX Biosimilar Insulin Market; 14.8.6.1. Introduction; 14.8.6.2. Market Analysis and Forecast by Market Taxonomy; 14.8.6.2.1. By Product; 14.8.6.2.2. By Distribution Channel; 14.8.7. Nordic Countries Biosimilar Insulin Market; 14.8.7.1. Introduction; 14.8.7.2. Market Analysis and Forecast by Market Taxonomy; 14.8.7.2.1. By Product; 14.8.7.2.2. By Distribution Channel; 14.8.8. Russia Biosimilar Insulin Market; 14.8.8.1. Introduction; 14.8.8.2. Market Analysis and Forecast by Market Taxonomy; 14.8.8.2.1. By Product; 14.8.8.2.2. By Distribution Channel
15. Asia Pacific (APAC) Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032: 15.1. Introduction; 15.2. Pricing Analysis; 15.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021; 15.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032; 15.4.1. By Country; 15.4.1.1. China; 15.4.1.2. Japan; 15.4.1.3. India; 15.4.1.4. Australia; 15.4.1.5. New Zealand; 15.4.2. By Product; 15.4.3. By Distribution Channel; 15.5. Market Attractiveness Analysis; 15.5.1. By Country; 15.5.2. By Product; 15.5.3. By Distribution Channel; 15.6. Key Market Participants - Intensity Mapping; 15.7. Drivers and Restraints - Impact Analysis; 15.8. Country Level Analysis & Forecast; 15.8.1. China Biosimilar Insulin Market; 15.8.1.1. Introduction; 15.8.1.2. Market Analysis and Forecast by Market Taxonomy; 15.8.1.2.1. By Product; 15.8.1.2.2. By Distribution Channel; 15.8.2. Japan Biosimilar Insulin Market; 15.8.2.1. Introduction; 15.8.2.2. Market Analysis and Forecast by Market Taxonomy; 15.8.2.2.1. By Product; 15.8.2.2.2. By Distribution Channel; 15.8.3. India Biosimilar Insulin Market; 15.8.3.1. Introduction; 15.8.3.2. Market Analysis and Forecast by Market Taxonomy; 15.8.3.2.1. By Product; 15.8.3.2.2. By Distribution Channel; 15.8.4. Australia Biosimilar Insulin Market; 15.8.4.1. Introduction; 15.8.4.2. Market Analysis and Forecast by Market Taxonomy; 15.8.4.2.1. By Product; 15.8.4.2.2. By Distribution Channel; 15.8.5. New Zealand Biosimilar Insulin Market; 15.8.5.1. Introduction; 15.8.5.2. Market Analysis and Forecast by Market Taxonomy; 15.8.5.2.1. By Product; 15.8.5.2.2. By Distribution Channel
16. Middle East and Africa (MEA) Biosimilar Insulin Market Analysis 2017–2021 and Forecast 2022–2032: 16.1. Introduction; 16.2. Pricing Analysis; 16.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021; 16.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032; 16.4.1. By Country; 16.4.1.1. GCC Countries; 16.4.1.2. Israel; 16.4.1.3. Turkey; 16.4.1.4. Egypt; 16.4.1.5. North Africa; 16.4.1.6. South Africa; 16.4.1.7. Rest of Middle East and Africa; 16.4.2. By Product; 16.4.3. By Distribution Channel; 16.5. Market Attractiveness Analysis; 16.5.1. By Country; 16.5.2. By Product; 16.5.3. By Distribution Channel; 16.6. Key Market Participants - Intensity Mapping; 16.7. Drivers and Restraints - Impact Analysis; 16.8. Country Level Analysis & Forecast; 16.8.1. GCC Countries Biosimilar Insulin Market; 16.8.1.1. Introduction; 16.8.1.2. Market Analysis and Forecast by Market Taxonomy; 16.8.1.2.1. By Product; 16.8.1.2.2. By Distribution Channel; 16.8.2. Israel Biosimilar Insulin Market; 16.8.2.1. Introduction; 16.8.2.2. Market Analysis and Forecast by Market Taxonomy; 16.8.2.2.1. By Product; 16.8.2.2.2. By Distribution Channel; 16.8.3. Turkey Biosimilar Insulin Market; 16.8.3.1. Introduction; 16.8.3.2. Market Analysis and Forecast by Market Taxonomy; 16.8.3.2.1. By Product; 16.8.3.2.2. By Distribution Channel; 16.8.4. Egypt Biosimilar Insulin Market; 16.8.4.1. Introduction; 16.8.4.2. Market Analysis and Forecast by Market Taxonomy; 16.8.4.2.1. By Product; 16.8.4.2.2. By Distribution Channel; 16.8.5. North Africa Biosimilar Insulin Market; 16.8.5.1. Introduction; 16.8.5.2. Market Analysis and Forecast by Market Taxonomy; 16.8.5.2.1. By Product; 16.8.5.2.2. By Distribution Channel; 16.8.6. South Africa Biosimilar Insulin Market; 16.8.6.1. Introduction; 16.8.6.2. Market Analysis and Forecast by Market Taxonomy; 16.8.6.2.1. By Product; 16.8.6.2.2. By Distribution Channel
17. Market Structure Analysis: 17.1. Market Analysis by Tier of Companies; 17.2. Market Share Analysis of Top Players; 17.3. Market Presence Analysis; 17.3.1. Regional footprint of Players; 17.3.2. Platform Type foot print by Players; 17.3.3. Channel Foot Print by Players
18. Competition Analysis: 18.1. Competition Dashboard; 18.2. Competition Benchmarking; 18.3. Competition Deep Dive; 18.3.1. Biocon; 18.3.1.1. Overview; 18.3.1.2. Product Portfolio; 18.3.1.3. Key Financials; 18.3.1.4. Geographical Footprint; 18.3.1.5. SWOT Analysis; 18.3.1.6. Key Developments; 18.3.1.7. Strategy Overview; 18.3.1.7.1. Channel Strategy; 18.3.1.7.2. Marketing Strategy; 18.3.1.7.3. Product Strategy; 18.3.2. Eli Lilly and Company; 18.3.2.1. Overview; 18.3.2.2. Product Portfolio; 18.3.2.3. Key Financials; 18.3.2.4. Geographical Footprint; 18.3.2.5. SWOT Analysis; 18.3.2.6. Key Developments; 18.3.2.7. Strategy Overview; 18.3.2.7.1. Channel Strategy; 18.3.2.7.2. Marketing Strategy; 18.3.2.7.3. Product Strategy; 18.3.3. Sanofi; 18.3.3.1. Overview; 18.3.3.2. Product Portfolio; 18.3.3.3. Key Financials; 18.3.3.4. Geographical Footprint; 18.3.3.5. SWOT Analysis; 18.3.3.6. Key Developments; 18.3.3.7. Strategy Overview; 18.3.3.7.1. Channel Strategy; 18.3.3.7.2. Marketing Strategy; 18.3.3.7.3. Product Strategy; 18.3.4. BGP Pharma; 18.3.4.1. Overview; 18.3.4.2. Product Portfolio; 18.3.4.3. Key Financials; 18.3.4.4. Geographical Footprint; 18.3.4.5. SWOT Analysis; 18.3.4.6. Key Developments; 18.3.4.7. Strategy Overview; 18.3.4.7.1. Channel Strategy; 18.3.4.7.2. Marketing Strategy; 18.3.4.7.3. Product Strategy; 18.3.5. Aspen; 18.3.5.1. Overview; 18.3.5.2. Product Portfolio; 18.3.5.3. Key Financials; 18.3.5.4. Geographical Footprint; 18.3.5.5. SWOT Analysis; 18.3.5.6. Key Developments; 18.3.5.7. Strategy Overview; 18.3.5.7.1. Channel Strategy; 18.3.5.7.2. Marketing Strategy; 18.3.5.7.3. Product Strategy; 18.3.6. Mylan (Viatris); 18.3.6.1. Overview; 18.3.6.2. Product Portfolio; 18.3.6.3. Key Financials; 18.3.6.4. Geographical Footprint; 18.3.6.5. SWOT Analysis; 18.3.6.6. Key Developments; 18.3.6.7. Strategy Overview; 18.3.6.7.1. Channel Strategy; 18.3.6.7.2. Marketing Strategy; 18.3.6.7.3. Product Strategy
19. Assumptions and Acronyms Used
20. Research Methodology